Jaewon Kim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jaewon Kim has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- Dong Keon Yon
Department of Medicine Kyung Hee University College of Medicine Seoul South Korea
4 shared publications Jiyoung Hwang
Center for Digital Health, Medical Science Research Institute, Kyung Hee University Medical Center, Kyung Hee University College of Medicine, Seoul, South Korea
2 shared publications- Sang Youl Rhee
Department of Endocrinology and Metabolism Kyung Hee University College of Medicine Seoul Republic of Korea
2 shared publications Yejun Son
Center for Digital Health, Medical Science Research Institute, Kyung Hee University Medical Center, Kyung Hee University College of Medicine, Seoul, South Korea
2 shared publicationsArianna R.S. Lark
Division of Sleep Medicine, Harvard Medical School, Boston, MA, USA; Mass General Brigham Department of Anesthesiology, Massachusetts General Hospital, Boston, MA, USA
1 shared publication- Christa J. Nehs
Mass General Brigham Department of Anesthesiology, Massachusetts General Hospital, Boston, MA, USA
1 shared publication
Latest Publications
- Open Access
- 13 June 2026
- Published by Elsevier in JAAD International
- Vol. 27, 149-159
Global patterns of melanoma, burden attributable to ultraviolet radiation exposure, and projections to 2050 across 185 countries: a population-based study with global modeling
- 13 June 2026
- Published by Elsevier in JAAD International
- Vol. 27, 149-159
Open AccessGlobal patterns of melanoma, burden attributable to ultraviolet radiation exposure, and projections to 2050 across 185 countries: a population-based study with global modeling
- Open Access
- 24 September 2025
- Published by MDPI AG in Diagnostics
- Vol. 15 (19) , 2433
Diagnostic Efficacy of Olfactory Function Test Using Functional Near-Infrared Spectroscopy with Machine Learning in Healthy Adults: A Prospective Diagnostic-Accuracy (Feasibility/Validation) Study in Healthy Adults with Algorithm Development
Background/Objectives: The YSK olfactory function (YOF) test is a culturally adapted psychophysical tool that assesses threshold, discrimination, and identification. This study evaluated whether functional near-infrared spectroscopy (fNIRS) synchronized with routine YOF testing, combined with machine learning, can predict YOF subdomain performance in healthy adults, providing an objective neural correlate to complement behavioral testing. Methods: In this prospective diagnostic-accuracy (feasibility/validation) study in healthy adults with algorithm development, 100 healthy adults completed the YOF test while undergoing prefrontal/orbitofrontal fNIRS during odor blocks. Feature sets from ΔHbO/ΔHbR included time-domain descriptors, complexity (Lempel–Ziv), and information-theoretic measures (mutual information); the identification task used a hybrid attention–CNN. Separate models were developed for threshold (binary classification), discrimination (binary classification), and identification (binary classification). Performance was summarized with accuracy, area under the curve (AUC), F1-score, and (where applicable) sensitivity/specificity, using participant-level cross-validation. Results: The threshold classifier achieved accuracy 0.86, AUC 0.86, and F1 0.86, indicating strong discrimination of correct vs. incorrect threshold responses. The discrimination model yielded accuracy 0.75, AUC 0.76, and F1 0.75. The identification model (attention–convolutional neural network [CNN]) achieved accuracy 0.88, sensitivity 0.86, specificity 0.91, and F1 0.88. Feature-attribution (e.g., SHapley Additive exPlanations [SHAP]) provided interpretable links between fNIRS features and task performance for threshold and discrimination. Conclusions: Olfactory-evoked fNIRS signals can accurately predict YOF subdomain performance in healthy adults, supporting the feasibility of non-invasive, portable, near–real-time olfactory monitoring. These findings are preliminary and not generalizable to clinical populations; external validation in diverse cohorts is warranted. The approach clarifies the scientific essence of the method by (i) aligning psychophysical outcomes with objective hemodynamic signatures and (ii) introducing a feature-rich modeling pipeline (ΔHbO/ΔHbR + Lempel–Ziv complexity/mutual information; attention–CNN) that advances prior work.
- 24 September 2025
- Published by MDPI AG in Diagnostics
- Vol. 15 (19) , 2433
Open AccessDiagnostic Efficacy of Olfactory Function Test Using Functional Near-Infrared Spectroscopy with Machine Learning in Healthy Adults: A Prospective Diagnostic-Accuracy (Feasibility/Validation) Study in Healthy Adults with Algorithm Development
Background/Objectives: The YSK olfactory function (YOF) test is a culturally adapted psychophysical tool that assesses threshold, discrimination, and identification. This study evaluated whether functional near-infrared spectroscopy (fNIRS) synchronized with routine YOF testing, combined with machine learning, can predict YOF subdomain performance in healthy adults, providing an objective neural correlate to complement behavioral testing. Methods: In this prospective diagnostic-accuracy (feasibility/validation) study in healthy adults with algorithm development, 100 healthy adults completed the YOF test while undergoing prefrontal/orbitofrontal fNIRS during odor blocks. Feature sets from ΔHbO/ΔHbR included time-domain descriptors, complexity (Lempel–Ziv), and information-theoretic measures (mutual information); the identification task used a hybrid attention–CNN. Separate models were developed for threshold (binary classification), discrimination (binary classification), and identification (binary classification). Performance was summarized with accuracy, area under the curve (AUC), F1-score, and (where applicable) sensitivity/specificity, using participant-level cross-validation. Results: The threshold classifier achieved accuracy 0.86, AUC 0.86, and F1 0.86, indicating strong discrimination of correct vs. incorrect threshold responses. The discrimination model yielded accuracy 0.75, AUC 0.76, and F1 0.75. The identification model (attention–convolutional neural network [CNN]) achieved accuracy 0.88, sensitivity 0.86, specificity 0.91, and F1 0.88. Feature-attribution (e.g., SHapley Additive exPlanations [SHAP]) provided interpretable links between fNIRS features and task performance for threshold and discrimination. Conclusions: Olfactory-evoked fNIRS signals can accurately predict YOF subdomain performance in healthy adults, supporting the feasibility of non-invasive, portable, near–real-time olfactory monitoring. These findings are preliminary and not generalizable to clinical populations; external validation in diverse cohorts is warranted. The approach clarifies the scientific essence of the method by (i) aligning psychophysical outcomes with objective hemodynamic signatures and (ii) introducing a feature-rich modeling pipeline (ΔHbO/ΔHbR + Lempel–Ziv complexity/mutual information; attention–CNN) that advances prior work.
- Open Access
- 17 July 2025
- Published by Elsevier in Journal of Advanced Research
- Vol. 82, 917-936
Biomarkers for Alzheimer’s disease across diverse biological domains: an umbrella review and evidence map
- 17 July 2025
- Published by Elsevier in Journal of Advanced Research
- Vol. 82, 917-936
Open AccessBiomarkers for Alzheimer’s disease across diverse biological domains: an umbrella review and evidence map
- Open Access
- 22 January 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (1) , e0315603
An anonymized, de-identified registry study protocol to determine the effectiveness and safety of weight loss with enavogliflozin in patients with type 2 diabetes mellitus
Sodium-glucose co-transporter 2 inhibitors, such as enavogliflozin, offer promising metabolic benefits for patients with type 2 diabetes (T2D), including glycemic control and improved cardiac function. Despite the clinical evidence, real-world evidence is needed to validate their safety and effectiveness. This study aims to evaluate the effects of weight loss and safety of enavogliflozin administration in patients with T2D in a real-world clinical setting over 24 weeks. This is a large-scale, prospective, multicenter, non-interventional observational study and will be conducted in 12 primary care centers nationwide between 2024 and 2026. Data will be collected at baseline, 12 weeks, and 24 weeks in a real-world clinical setting, including demographic details, clinical history, lifestyle habits, medication use, and various health indicators. Eligible participants are adults aged 19 to 80 with T2D and a body mass index (BMI) of ≥23 kg/m2 who are currently receiving treatment with Envlo (enavogliflozin) or Envlomet (enavogliflozin/metformin) tablets or planning to start treatment. The primary outcome is the change in BMI and body weight at 24 weeks from baseline. Secondary outcomes evaluated are changes in BMI and weight at 12 weeks, the proportion of participants achieving significant reductions in BMI and weight at 12 and 24 weeks, and body composition and glycemic improvements at 12 and 24 weeks. The study will analyze shifts in lipid profiles, liver and kidney functions, and body composition at 12 and 24 weeks as exploratory outcomes. For safety outcomes, the trial will prioritize the monitoring of adverse drug reactions and specific events of interest such as hypoglycemia, urinary tract infections, genital infections, polyuria, and polydipsia. This study design enables us to evaluate the effectiveness and safety of enavogliflozin for weight loss in a real-world setting while exploring its potential positive effects on cardiac function and metabolic risk factors in overweight or obese patients with T2D.
- 22 January 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (1) , e0315603
Open AccessAn anonymized, de-identified registry study protocol to determine the effectiveness and safety of weight loss with enavogliflozin in patients with type 2 diabetes mellitus
Sodium-glucose co-transporter 2 inhibitors, such as enavogliflozin, offer promising metabolic benefits for patients with type 2 diabetes (T2D), including glycemic control and improved cardiac function. Despite the clinical evidence, real-world evidence is needed to validate their safety and effectiveness. This study aims to evaluate the effects of weight loss and safety of enavogliflozin administration in patients with T2D in a real-world clinical setting over 24 weeks. This is a large-scale, prospective, multicenter, non-interventional observational study and will be conducted in 12 primary care centers nationwide between 2024 and 2026. Data will be collected at baseline, 12 weeks, and 24 weeks in a real-world clinical setting, including demographic details, clinical history, lifestyle habits, medication use, and various health indicators. Eligible participants are adults aged 19 to 80 with T2D and a body mass index (BMI) of ≥23 kg/m2 who are currently receiving treatment with Envlo (enavogliflozin) or Envlomet (enavogliflozin/metformin) tablets or planning to start treatment. The primary outcome is the change in BMI and body weight at 24 weeks from baseline. Secondary outcomes evaluated are changes in BMI and weight at 12 weeks, the proportion of participants achieving significant reductions in BMI and weight at 12 and 24 weeks, and body composition and glycemic improvements at 12 and 24 weeks. The study will analyze shifts in lipid profiles, liver and kidney functions, and body composition at 12 and 24 weeks as exploratory outcomes. For safety outcomes, the trial will prioritize the monitoring of adverse drug reactions and specific events of interest such as hypoglycemia, urinary tract infections, genital infections, polyuria, and polydipsia. This study design enables us to evaluate the effectiveness and safety of enavogliflozin for weight loss in a real-world setting while exploring its potential positive effects on cardiac function and metabolic risk factors in overweight or obese patients with T2D.
- Open Access
- 1 January 2023
- Published by XMLink in Digital Health Research
- Vol. 1 (1)
Effect of Statin on All-Cause Mortality in the Older Adults: A Population-based Cohort Study
Kim S, et al. Digit Health Res. 2023 Sep;1(1):e4. https://doi.org/10.61499/dhr.2023.1.e4
- 1 January 2023
- Published by XMLink in Digital Health Research
- Vol. 1 (1)
Open AccessEffect of Statin on All-Cause Mortality in the Older Adults: A Population-based Cohort Study
Kim S, et al. Digit Health Res. 2023 Sep;1(1):e4. https://doi.org/10.61499/dhr.2023.1.e4